JP2023516648A - 真菌感染症の処置における化合物の使用 - Google Patents

真菌感染症の処置における化合物の使用 Download PDF

Info

Publication number
JP2023516648A
JP2023516648A JP2022552405A JP2022552405A JP2023516648A JP 2023516648 A JP2023516648 A JP 2023516648A JP 2022552405 A JP2022552405 A JP 2022552405A JP 2022552405 A JP2022552405 A JP 2022552405A JP 2023516648 A JP2023516648 A JP 2023516648A
Authority
JP
Japan
Prior art keywords
spp
compound
acceptable salt
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516648A5 (https=
Inventor
ホッジス マイケル
ジョイ ショー カレン
Original Assignee
アンプリックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンプリックス ファーマシューティカルズ，インク． filed Critical アンプリックス ファーマシューティカルズ，インク．
Publication of JP2023516648A publication Critical patent/JP2023516648A/ja
Publication of JP2023516648A5 publication Critical patent/JP2023516648A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022552405A 2020-03-04 2021-03-02 真菌感染症の処置における化合物の使用 Pending JP2023516648A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985274P 2020-03-04 2020-03-04
US62/985,274 2020-03-04
PCT/US2021/020471 WO2021178406A1 (en) 2020-03-04 2021-03-02 Use of compounds in the treatment of fungal infections

Publications (2)

Publication Number Publication Date
JP2023516648A true JP2023516648A (ja) 2023-04-20
JP2023516648A5 JP2023516648A5 (https=) 2024-04-08

Family

ID=77612811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552405A Pending JP2023516648A (ja) 2020-03-04 2021-03-02 真菌感染症の処置における化合物の使用

Country Status (11)

Country Link
US (2) US12521406B2 (https=)
EP (1) EP4114405A4 (https=)
JP (1) JP2023516648A (https=)
KR (1) KR20220148881A (https=)
CN (1) CN115515599A (https=)
AU (1) AU2021230529B2 (https=)
BR (1) BR112022017653A2 (https=)
CA (1) CA3174065A1 (https=)
IL (1) IL296093A (https=)
MX (1) MX2022010804A (https=)
WO (1) WO2021178406A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530936A (ja) * 2020-06-17 2023-07-20 アンプリックス ファーマシューティカルズ，インク． 真菌感染症を処置するための化合物および方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116687929B (zh) * 2023-06-16 2026-04-28 山东省妇幼保健院 血根碱在制备防治临床罕见真菌相关感染性疾病药物中的应用
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
CN119915948B (zh) * 2025-04-02 2025-07-08 天津辰欣药物研究有限公司 一种小分子真菌肌醇酰基转移酶1抑制剂原料药中致突变杂质的分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2345641A1 (en) 2009-12-29 2011-07-20 Polichem S.A. New secondary 8-hydroxyquinoline-7-carboxamide derivatives
IL275121B2 (en) * 2017-12-07 2025-11-01 Amplyx Pharmaceuticals Inc Heterocycle substituted pyridine derivative antifungal agents
WO2020047510A1 (en) 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
CA3187268A1 (en) 2020-06-17 2021-12-23 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060448A1 (ja) * 2010-11-05 2012-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗真菌剤としての併用医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"1840. First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administere", OPEN FORUM INFECTIOUS DISEASES, vol. 4(Suppl 1), JPN7025000831, 2017, pages 526, ISSN: 0005764962 *
"1860. Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral", OPEN FORUM INFECTIOUS DISEASES, vol. 4(Suppl 1), JPN7025000833, 2017, pages 534, ISSN: 0005764963 *
"An Open-label Study of APX001for Treatment of Patients With Candidemia/ Invasive Candidiasis Caused", CLINICALTRIALS.GOV, vol. NCT04148287, JPN7025000832, 1 November 2019 (2019-11-01), pages 1 - 7, ISSN: 0005764964 *
"APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 63(2)e01713-18, JPN7025000834, 2019, pages 1 - 9, ISSN: 0005764961 *
"Hope on the Horizon: Novel FungalTreatments in Development", OPEN FORUM INFECTIOUS DISEASES, vol. 7(2), JPN7025000835, 12 January 2020 (2020-01-12), pages 1 - 19, ISSN: 0005764960 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530936A (ja) * 2020-06-17 2023-07-20 アンプリックス ファーマシューティカルズ，インク． 真菌感染症を処置するための化合物および方法

Also Published As

Publication number Publication date
US20260102419A1 (en) 2026-04-16
CA3174065A1 (en) 2021-09-10
AU2021230529A1 (en) 2022-09-29
NZ792042A (en) 2025-09-26
AU2021230529B2 (en) 2024-09-05
EP4114405A4 (en) 2024-03-13
WO2021178406A1 (en) 2021-09-10
KR20220148881A (ko) 2022-11-07
US12521406B2 (en) 2026-01-13
EP4114405A1 (en) 2023-01-11
US20230102036A1 (en) 2023-03-30
CN115515599A (zh) 2022-12-23
BR112022017653A2 (pt) 2022-10-18
MX2022010804A (es) 2023-01-16
IL296093A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US12521406B2 (en) Use of compounds in the treatment of fungal infections
JP2017533944A (ja) Ｔｌｒ阻害剤及びブルトンチロシンキナーゼ阻害剤の併用
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
TW200808313A (en) Compositions and methods for treating rheumatoid arthritis
TW202333731A (zh) 用於治療癌症之VCP/p97抑制劑
AU2021293911B2 (en) Compounds and methods for treating fungal infections
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
Heitmann et al. Right-sided pacemaker-related endocarditis due to Acremonium species
JP7454905B2 (ja) 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
Groll et al. Fungal infections in pediatric patients
US20240245666A1 (en) Dosing regimens
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
HK40085944A (en) Compounds and methods for treating fungal infections
US20240366599A1 (en) Human efficacious dose and dosage schedule of spr720
US20240082229A1 (en) Methods for preventing or treating h. pylori infection
TWI914354B (zh) 用於治療癌症之VCP/p97抑制劑
WO2025208442A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
US20250302821A1 (en) Synergistic antifungal composition and method
Blash Systemic Candida Infections in Patients With Leukemia: An Overview of Drug Therapy.
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260311